16 February 2009--Synthon is pleased to announce that it has successfully completed multiple decentralized procedures (DCP) for its newest product within its comprehensive portfolio: Montelukast. Regulatory clearance has been obtained for Synthon's product in sixteen European countries. Registration has been obtained for multiple dosage forms including a filmcoated tablet, intended for adults aged 15 years and above, and a chewable dosage form, intended for children aged 2 -14 years.
The details can be read here.
No comments:
Post a Comment